Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 14 recruiting now early-phase tilt

Skin Cancer: early-phase trial registry

14 of 42 indexed Skin Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #347 of 28,707 conditions by registered trial count.

42 US clinical trials · 14 currently recruiting · #347 of 28,707 conditions by registered trial count

Skin Cancer: 42 US clinical trials tracked, 14 recruiting.

Skin Cancer is the subject of 42 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 5 of these trials.

Enrollment posture brief

Registry condition skin-cancer

OPEN 14 | RECR 33% | LATE 3 | EARLY 16 | RANK #347 | SPON 5

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Gestational Diabetes64.3%Essential Tremor57.1%Epithelial Ovarian Cancer42.9%Skin Cancer (this)33%Dry Eye21.4%
Open-enrollment share among volume-matched conditions near Skin Cancer

Skin Cancer lists 14 open slots (33% of 42 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Skin Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Skin Cancer is recruiting below its size-band peers.

    14 of 42 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Skin Cancer trials is spread across many organizations.

    H. Lee Moffitt Cancer Center and Research Institute accounts for 5 of 42 trials (11.9%). 30 distinct sponsors appear on at least one study for this condition label.

  3. Most Skin Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 75 among the 41 trials that report a genuine target (sentinel values excluded). 25 of those (61%) plan for fewer than 100 participants.

  4. Skin Cancer research is mostly interventional.

    33 interventional and 9 observational studies make up this index (78.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 18Phase 28Phase 32Phase 41

Open and recent trials

42 total, page 1 of 1

RECRUITING NA 2,900 participants

Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs

H. Lee Moffitt Cancer Center and Research Institute

NCT07222995

RECRUITING NA 843 participants

Rural Adult and Youth Sun Protection Study

University of Utah

NCT06439979

RECRUITING Phase 3 528 participants

Undergraduate Skin Cancer Prevention Trial

University of Utah

NCT05634252

RECRUITING NA 400 participants

Adaptive Symptom Self-Management Immunotherapy Study

University of Arizona

NCT05715255

RECRUITING Phase 4 300 participants

Meloxicam in Mohs Micrographic Surgery

University of Oklahoma

NCT07200544

RECRUITING Phase 1 100 participants

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Bruce Robinson, MD

NCT07010692

RECRUITING NA 48 participants

DNA Repair Activity in the Skin of Day and Night Shift Workers

Wright State University

NCT04122456

RECRUITING NA 40 participants

High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

Dana-Farber Cancer Institute

NCT06298734

RECRUITING Phase 2 37 participants

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Massachusetts General Hospital

NCT05779423

RECRUITING Early Phase 1 30 participants

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Rhode Island Hospital

NCT05702398

RECRUITING Early Phase 1 25 participants

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Dana-Farber Cancer Institute

NCT06664151

RECRUITING 20 participants

Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

University of Wisconsin, Madison

NCT06608511

RECRUITING 20 participants

Raman Spectroscopy and Skin Cancer

Renee Farrell

NCT06384924

RECRUITING Phase 2 14 participants

TIL Therapy in cSCC and MCC

Karam Khaddour, MD, MS

NCT07288073

ACTIVE NOT RECRUITING 4,082 participants

A Model for Genetic Susceptibility: Melanoma

Memorial Sloan Kettering Cancer Center

NCT00591500

ACTIVE NOT RECRUITING 1,889 participants

In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin

Memorial Sloan Kettering Cancer Center

NCT00588315

ACTIVE NOT RECRUITING 354 participants

Patient Satisfaction in Cutaneous Surgery

Northwestern University

NCT01535963

ACTIVE NOT RECRUITING Phase 2 50 participants

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

NCT03071406

ACTIVE NOT RECRUITING NA 45 participants

A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.

NYU Langone Health

NCT07177638

ACTIVE NOT RECRUITING Phase 1 39 participants

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

NCT05704985

ACTIVE NOT RECRUITING Phase 2 34 participants

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Memorial Sloan Kettering Cancer Center

NCT05574101

ACTIVE NOT RECRUITING Phase 1 26 participants

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

NCT02721459

ACTIVE NOT RECRUITING Early Phase 1 14 participants

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

H. Lee Moffitt Cancer Center and Research Institute

NCT03543969

COMPLETED Phase 3 2,223 participants

Sun-safe Habits Intervention and Education

University of Utah

NCT04341064

COMPLETED NA 1,364 participants

Online Tailored Interventions & Relational Agents for Exercise and Sun Protection

University of Rhode Island

NCT01458002

COMPLETED 1,028 participants

DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer

DermaSensor

NCT06690086

COMPLETED Phase 2 867 participants

Skin Cancer Prevention in a Pediatric Population

University of Colorado, Denver

NCT01464957

COMPLETED NA 323 participants

Melanoma Risk Assessment & Tailored Intervention

University of Pennsylvania

NCT01356771

COMPLETED NA 170 participants

Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event

University of California, Davis

NCT01820234

COMPLETED Phase 2 133 participants

Phase II Trial of Allovectin-7® for Metastatic Melanoma

Vical

NCT00044356

COMPLETED NA 94 participants

Comparison Of Video-based Versus Written Patient Education on Sunscreen

University of California, Davis

NCT00826306

COMPLETED NA 89 participants

Effects of Lavender Aromatherapy on Patient Anxiety During Mohs Micrographic Surgery

Case Comprehensive Cancer Center

NCT06167096

COMPLETED 81 participants

Multi-Center Study to Evaluate the Performance of DermDx for Primary Care Physicians in the Detection of Skin Cancers

MetaOptima Technology

NCT06463860

COMPLETED NA 78 participants

EUREKA: Evaluating Ultraviolet Radiation Exposure in Kids for Adaptive Intervention

University of Utah

NCT07204704

COMPLETED NA 75 participants

Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery

Mayo Clinic

NCT00578214

COMPLETED 60 participants

Development and Validation of a New Digital Dermatoscope in the United States

Barco

NCT04047316

COMPLETED 42 participants

Health Communication in Families

Memorial Sloan Kettering Cancer Center

NCT00597961

COMPLETED Phase 1 30 participants

Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen

Yale University

NCT05736224

COMPLETED NA 29 participants

Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer

Emory University

NCT01526486

COMPLETED Phase 2 24 participants

Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

Sue Yom

NCT01835626

COMPLETED Phase 1 17 participants

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

NCT02032810

COMPLETED Phase 2

Study of Talabostat and Cisplatin in Advanced Melanoma

Point Therapeutics

NCT00083252

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 8
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Skin Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ipilimumab Drug
3 trials
Nivolumab Drug
3 trials
Radiation therapy Radiation
2 trials
UV Light Other
1 trials
Sunscreen Drug
1 trials
SHINE Intervention Behavioral
1 trials
Semi-tailored newsletter Behavioral
1 trials
Allovectin-7® Genetic
1 trials

US sites by state

Facility locations filed on Skin Cancer trials. A trial with sites in several states counts in each.

New York 12 trials
Florida 7 trials
California 6 trials
Utah 4 trials
Ohio 4 trials
Massachusetts 4 trials
Colorado 4 trials
Washington 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Skin Cancer page

42 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Skin Cancer condition card totals 42 registered trials; most-linked intervention Ipilimumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.